SUBOXONE Drug Patent Profile

Which patents cover Suboxone, and when can generic versions of Suboxone launch?

Suboxone is a drug marketed by Indivior and is included in two NDAs. There are three patents protecting this drug and three Paragraph IV challenges.

This drug has thirty-two patent family members in twenty-four countries.

The generic ingredient in SUBOXONE is buprenorphine hydrochloride; naloxone hydrochloride. There are twenty-nine drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the buprenorphine hydrochloride; naloxone hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Suboxone

A generic version of SUBOXONE was approved as buprenorphine hydrochloride; naloxone hydrochloride by ACTAVIS ELIZABETH on February 22^nd, 2013.

Summary for SUBOXONE

International Patents:	32
US Patents:	3
Applicants:	1
NDAs:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SUBOXONE

Paragraph IV (Patent) Challenges for SUBOXONE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SUBOXONE	Sublingual Film	buprenorphine hydrochloride; naloxone hydrochloride	12 mg/3 mg	022410	1	2013-05-14
SUBOXONE	Sublingual Film	buprenorphine hydrochloride; naloxone hydrochloride	2 mg/0.5 mg* and 8 mg/2 mg	022410	1	2012-10-15
SUBOXONE	for Injection	buprenorphine hydrochloride; naloxone hydrochloride	500 mg/vial	020733	2	2009-01-26

US Patents and Regulatory Information for SUBOXONE

SUBOXONE is protected by three US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Indivior	SUBOXONE	buprenorphine hydrochloride; naloxone hydrochloride	FILM;BUCCAL, SUBLINGUAL	022410-001	Aug 30, 2010	AB	RX	Yes	No	9,687,454		Y
Indivior	SUBOXONE	buprenorphine hydrochloride; naloxone hydrochloride	FILM;BUCCAL, SUBLINGUAL	022410-002	Aug 30, 2010	AB	RX	Yes	No	8,475,832		Y
Indivior	SUBOXONE	buprenorphine hydrochloride; naloxone hydrochloride	FILM;BUCCAL, SUBLINGUAL	022410-003	Aug 10, 2012	AB	RX	Yes	No	9,687,454		Y
Indivior	SUBOXONE	buprenorphine hydrochloride; naloxone hydrochloride	FILM;BUCCAL, SUBLINGUAL	022410-004	Aug 10, 2012	AB	RX	Yes	Yes	11,135,216		Y

International Patents for SUBOXONE

When does loss-of-exclusivity occur for SUBOXONE?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Croatia

Denmark

European Patent Office

Hong Kong

Israel

Japan

Malaysia

Mexico

New Zealand

Peru

Russian Federation

Singapore

South Africa

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering SUBOXONE around the world.

Country	Patent Number	Title	Estimated Expiration
Brazil	112012002817	composições sublinguais e bucais em filme
Japan	5160229
China	100445788
Mexico	PA05012815	PELICULAS BASADAS EN OXIDO DE POLIETILENO Y SISTEMAS PARA SUMINISTRO DE FÁRMACOS ELABORADOS CON ELLAS. (POLYETHYLENE OXIDE-BASED FILMS AND DRUG DELIVERY SYSTEMS MADE THEREFROM.)

Suboxone Investment Analysis: Patent Landscape and Market Dynamics

Last updated: February 19, 2026

Suboxone, a combination of buprenorphine and naloxone, is a leading medication-assisted treatment (MAT) for opioid use disorder (OUD). Its market position is influenced by its patent protection, generic competition, and evolving regulatory and reimbursement landscapes. This analysis examines the critical factors for investment consideration.

What is the patent status of Suboxone?

The original U.S. patent for Suboxone (buprenorphine and naloxone sublingual film) expired in 2009. However, Reckitt Benckiser Pharmaceuticals (now Indivior PLC) has pursued strategies to extend market exclusivity.

• Original Composition of Matter Patent: Expired.
• Formulation Patents: Indivior has obtained and defended patents related to specific formulations, including the sublingual film. For instance, U.S. Patent No. 8,747,855, which covers the Suboxone sublingual film formulation, was a key patent Indivior defended against ANDA filers.
• Patent Litigation and Exclusivity: Indivior has engaged in extensive patent litigation to prevent generic entry. Court decisions have varied, impacting the timeline for generic availability. For example, in 2019, the U.S. Court of Appeals for the Federal Circuit upheld the validity of U.S. Patent No. 8,747,855, providing Indivior with a period of exclusivity [1].
• Upcoming Patent Expirations: While the core composition patents are long expired, the protection afforded by formulation and manufacturing process patents is crucial. The lifespan of these secondary patents dictates the window for continued market exclusivity for branded Suboxone.

Who are the key players in the Suboxone market?

Indivior PLC is the primary manufacturer and marketer of branded Suboxone. The competitive landscape includes generic manufacturers seeking to enter the market.

• Indivior PLC: Holds the original Suboxone brand and has developed multiple delivery forms, including the sublingual film and the buprenorphine/naloxone sublingual tablet.
• Generic Manufacturers: Companies like Teva Pharmaceuticals, Dr. Reddy's Laboratories, and Sunrise Pharmaceuticals have sought U.S. Food and Drug Administration (FDA) approval for generic versions of buprenorphine/naloxone products. The timing and success of their ANDA filings and subsequent market entry are contingent on patent challenges and regulatory approvals.
• Competitors in MAT: Other medications for OUD, such as methadone and naltrexone, and newer buprenorphine-based products (e.g., Sublocade, a long-acting injectable), compete for market share.

What is the market size and growth potential for Suboxone and similar OUD treatments?

The market for OUD treatments is substantial and projected to grow, driven by increasing recognition of the opioid crisis and expanding access to care.

• Market Size: The global OUD treatment market was valued at approximately $4.9 billion in 2021 and is forecast to grow. Suboxone has historically been a dominant player in this market, particularly within the U.S. [2].
• Growth Drivers:
  • Epidemic Severity: The ongoing opioid epidemic in the U.S. and globally leads to increased demand for effective treatments.
  • Policy Support: Government initiatives and increased insurance coverage for OUD treatment expand patient access.
  • Shift Towards MAT: A growing consensus among healthcare professionals favors MAT, with buprenorphine-based treatments like Suboxone being a cornerstone.
  • Product Innovation: Development of new formulations (e.g., injections, implants) and delivery systems aims to improve patient adherence and outcomes, potentially expanding the overall market [3].
• Projected Growth: Market research reports project a compound annual growth rate (CAGR) for the OUD treatment market ranging from 5% to 10% over the next five to seven years, indicating sustained demand for effective therapies.

What are the regulatory and reimbursement considerations for Suboxone?

Regulatory approvals and favorable reimbursement policies are critical for market access and profitability.

• FDA Approval Process: Generic versions of buprenorphine/naloxone must undergo the FDA's Abbreviated New Drug Application (ANDA) process, demonstrating bioequivalence to the branded product.
• DEA Scheduling: Buprenorphine is a Schedule III controlled substance under the Controlled Substances Act (CSA), requiring specific prescribing and dispensing regulations. These regulations have evolved, with efforts to reduce barriers to prescribing, such as the elimination of the X-waiver requirement for physicians prescribing buprenorphine in 2023 [4].
• Reimbursement Landscape:
  • Medicaid and Medicare: These programs are significant payers for OUD treatments. Coverage policies for buprenorphine/naloxone products are generally favorable but can vary by state and plan.
  • Commercial Insurance: Coverage by private insurers is widespread, though prior authorization requirements or step-therapy protocols can influence prescribing patterns.
  • PBMs and Rebates: Pharmacy benefit managers (PBMs) play a role in formulary placement and cost negotiations, impacting net pricing.
• Impact of Generic Entry on Pricing: The introduction of generic buprenorphine/naloxone is expected to lead to significant price erosion for the branded product, impacting revenue streams for Indivior.

What are the risks and challenges associated with Suboxone investment?

Investment in Suboxone and its related market faces several risks.

• Generic Competition: The primary risk is the continued and increasing availability of lower-cost generic alternatives, which directly erodes the market share and pricing power of branded Suboxone.
• Litigation Risks: Ongoing patent litigation can result in unfavorable outcomes for the patent holder, accelerating generic entry.
• Purity Concerns and Counterfeiting: The illicit market for Suboxone, particularly counterfeit pills, poses a significant public health risk and can impact legitimate market dynamics. While not a direct investment risk for manufacturers of the approved product, it highlights the complexities of the buprenorphine market.
• Shifting Treatment Modalities: The development and adoption of alternative OUD treatments, such as long-acting injectables (e.g., Indivior's own Sublocade) or newer pharmacological approaches, could divert market share from oral formulations.
• Regulatory Changes: Unforeseen changes in prescribing regulations or reimbursement policies could adversely affect market access and demand.
• Manufacturing and Supply Chain: Ensuring a consistent and high-quality supply chain is critical, with potential disruptions from raw material availability or geopolitical factors.

What are the strategic opportunities for stakeholders in the Suboxone ecosystem?

Despite the challenges, opportunities exist for companies involved in OUD treatment.

• Generic Manufacturing: Companies can capitalize on the large and growing demand for affordable buprenorphine/naloxone by securing FDA approval for generic versions and establishing efficient manufacturing and distribution channels.
• Product Differentiation: Developing novel formulations or delivery systems (e.g., extended-release, novel combinations, or alternative administration routes) can create new market segments and extend product lifecycles. Indivior's development of Sublocade is an example of this strategy.
• Geographic Expansion: Expanding access to Suboxone and other MATs in underserved regions or countries with a growing opioid crisis presents significant growth potential.
• Integrated Care Models: Companies that can offer integrated solutions, including pharmaceuticals, digital health tools for patient monitoring, and support services, may gain a competitive advantage.
• Partnerships and Acquisitions: Strategic partnerships or acquisitions can accelerate market entry, expand product portfolios, or secure intellectual property.

Key Takeaways

• Suboxone's patent protection has been a complex and evolving landscape, with original composition patents expired but formulation patents providing extended exclusivity.
• Indivior PLC is the primary stakeholder for branded Suboxone, facing increasing competition from generic manufacturers.
• The market for OUD treatments is substantial and growing, driven by the opioid crisis and supportive policy changes.
• Regulatory factors, particularly controlled substance scheduling and prescribing requirements, alongside reimbursement policies from Medicaid, Medicare, and commercial insurers, critically influence market access.
• The primary investment risks include intensifying generic competition and potential shifts towards alternative treatment modalities.
• Opportunities lie in generic production, product innovation, geographic expansion, and integrated care solutions.

Frequently Asked Questions

1. When did the core patent for Suboxone expire? The original U.S. patent for Suboxone expired in 2009.

2. What is the primary mechanism through which generic competition impacts Suboxone revenue? Generic competition impacts Suboxone revenue primarily through significant price erosion and loss of market share to lower-cost alternatives.

3. How has the DEA X-waiver elimination affected Suboxone prescribing? The elimination of the DEA X-waiver in 2023 removed a barrier to buprenorphine prescribing, potentially increasing patient access and demand for medications like Suboxone.

4. Are there alternative delivery methods for buprenorphine/naloxone that compete with Suboxone film? Yes, alternatives include buprenorphine/naloxone sublingual tablets, as well as long-acting injectable formulations such as Sublocade, which offer different patient adherence profiles.

5. What is the projected future trend for the market of opioid use disorder treatments? The market for opioid use disorder treatments is projected for continued growth, with estimates suggesting a compound annual growth rate between 5% and 10% over the next several years.

Citations

[1] U.S. Court of Appeals for the Federal Circuit. (2019). Indivior Inc. v. Teva Pharmaceuticals USA, Inc. Case No. 18-1776. [2] Grand View Research. (2022). Opioid Use Disorder Treatment Market Size, Share & Trends Analysis Report. [3] Mordor Intelligence. (2023). Opioid Use Disorder Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028). [4] Substance Abuse and Mental Health Services Administration. (2023). Elimination of the X Waiver. Retrieved from https://www.samhsa.gov/medications-substance-use-disorders/clinical-practice/x-waiver-elimination